不同去势方式治疗晚期前列腺癌的现状及进展

程双蕾; 岳中瑾; 符小宝; 何伸宝; 吴恭瑾

doi:10.13201/j.issn.1001-1420.2016.10.025

不同去势方式治疗晚期前列腺癌的现状及进展

- 兰州大学第二医院泌尿外科(兰州,730030)

详细信息

通讯作者: 吴恭瑾,E-mail:gongjinwu@126.com

中图分类号: R737.25

收稿日期: 2016-06-19

Current status and progress of different methods of castration for treatment of advanced prostate cancer

- Department of Urology,Second Hospital of Lanzhou University,Lanzhou, 730030, China

More Information

Corresponding author: WU Gongjin, E-mail: gongjinwu@126.com

Received Date: 19 June 2016

摘要

摘要: 前列腺癌是老年男性常见的疾病之一,发现时多为晚期。对于晚期前列腺癌而言,其首选的治疗手段为内分泌治疗,其中以最大雄激素阻断疗法即去势+抗雄激素治疗最为常用,有关去势方式又可分为手术去势和药物去势。目前临床上对于手术或药物去势的选择虽有大量文献进行比较分析,但尚无统一的选择标准。本文就晚期前列腺癌内分泌治疗中不同去势方式的选择做一综述。
- 晚期前列腺癌 /
- 手术去势 /
- 药物去势
Abstract: Prostate cancer is one of the common diseases in the elderly.It is found mostly late.Endocrine therapy is the first choice for the treatment of advanced prostate cancer,and maximum androgen blockade therapy,namely as castration plus anti-androgen treatment is most commonly used at present.The ways of castration can be classified as surgical castration and medical castration.There is still no uniform standard,though a large amount of literature has analyzed and compared between these two methods.In this paper,the selection of different methods of castration for the treatment of advanced prostate cancer will be reviewed.
- advanced prostate cancer /
- surgical castration /
- medical castration

HTML全文

参考文献(27)

[1]	Heidenreich A,Bellmunt J,Bolla M,et al.EAUguidelines on prostate cancer.Part 1:screening,diagnosis,and treatment of clinically localised disease[J].Eur Urol,2011,59(1):61-71.
[2]	Kunath F,Grobe H R,Rucker G,et al.Non-steroidal antiandrogen monotherapy compared with luteinizing hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer:a Cochrane systematic review[J].BJU Int,2015,116(1):30-36.
[3]	Ayyathurai R,Santos R L,Manoharan M.Role of maximum androgen blockade in advanced prostate cancer[J].Indian J Urol,2009,25(1):47-51.
[4]	Labrie F.GnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer[J].Endocr Relat Cancer,2014,21(4):R301-R317.
[5]	那彦群,叶章群,孙颖浩,等主编.2014版中国泌尿外科疾病诊断治疗指南[M].北京:人民卫生出版社,2014:72.
[6]	Zhang X Z,Donovan M P,Williams B T,et al.Comparison of subcapsular and total orchiectomy for treatment of metastatic prostate cancer[J].Urology,1996,47(3):402-404.
[7]	蒋玉清,吴国柱,王伟,等.手术去势和药物去势治疗前列腺癌疗效的回顾性研究[J].河北医药,2015,37(21):3234-3236.
[8]	孙颖浩,高旭.前列腺癌内分泌治疗的合理选择[J].现代泌尿外科杂志,2007,12(1):1-3.
[9]	Armstrong A J,Garrett-Mayer E,de Wit R,et al.Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer[J].Clin Cancer Res,2010,16(1):203-211.
[10]	Weckermann D,Harzmann R.Hormone therapy in prostate cancer:LHRH antagonists versus LHRH analogues[J].Eur Urol,2004,46(3):279-283,283-284.
[11]	Labrie F,Belanger A,Luu-The V,et al.Gonadotropin-releasing hormone agonists in the treatment of prostate cancer[J].Endocr Rev,2005,26(3):361-379.
[12]	Seidenfeld J,Samson D J,Hasselblad V,et al.Singletherapy androgen suppression in men with advanced prostate cancer:a systematic review and meta-analysis[J].Ann Intern Med,2000,132(7):566-577.
[13]	乔明洲,宋歌,张海芳.醋酸戈舍瑞林缓释植入剂与手术去势联合比卡鲁胺片治疗晚期前列腺癌的疗效比较[J].中国继续医学教育,2016,8(4):182-183.
[14]	Oefelein M G,Feng A,Scolieri M J,et al.Reassessment of the definition of castrate levels of testosterone:implications for clinical decision making[J].Urology,2000,56(6):1021-1024.
[15]	Novara G,Galfano A,Secco S,et al.Impact of surgical and medical castration on serum testosterone level in prostate cancer patients[J].Urol Int,2009,82(3):249-255.
[16]	Crawford E D,Moul J W,Sartor O,et al.Extended release,6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer:achieving testosterone levels below 20 ng/dl[J].Expert Opin Drug Metab Toxicol,2015,11(9):1465-1474.
[17]	van der Sluis T M,Bui H N,Meuleman E J,et al.Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration:new insights attained by mass spectrometry[J].J Urol,2012,187(5):1601-1606.
[18]	华立新,吴宏飞,眭元庚,等.药物去势和手术去势对前列腺癌患者性激素的影响[J].中华泌尿外科杂志,2005,26(12):812-815.
[19]	Sun M,Choueiri T K,Hamnvik O P,et al.Comparison of gonadotropin-releasing hormone agonists and orchiectomy:effects of androgen-deprivation therapy.[J].JAMA Oncol,2016,2(4):500-507.
[20]	Burki T K.Variation in prostate cancer management[J].Lancet Oncol,2014,15(10):e419.
[21]	余凯远,翁志梁,王思齐,等.间歇性与持续性雄激素阻断治疗晚期前列腺癌疗效比较[J].中华泌尿外科杂志,2006,27(11):761-764.
[22]	Mariani A J,Glover M,Arita S.Medical versus surgical androgen suppression therapy for prostate cancer:a 10-year longitudinal cost study[J].J Urol,2001,165(1):104-107.
[23]	Morrison B F,Aiken W D,Reid M E.Impact of the National Health Fund policy on hormone treatment for prostate cancer in Jamaica[J].Rev Panam Salud Publica,2011,29(6):404-408.
[24]	Chen C D,Welsbie D S,Tran C,et al.Molecular determinants of resistance to antiandrogen therapy[J].Nat Med,2004,10(1):33-39.
[25]	Calais da Silva F,Calais da Silva F M,Gonçalves F,et al.Locally advanced and metastatic prostate cancer treated with intermittent androgen monotherapy or maximal androgen blockade:results from a randomised phase 3study by the South European Uroncological Group[J].Eur Urol,2014,66(2):232-239.
[26]	Kang Y J,Kim K H,Lee K S.Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer[J].Korean J Urol,2014,55(5):315-320.
[27]	Bourke L,Kirkbride P,Hooper R,et al.Endocrine therapy in prostate cancer:time for reappraisal of risks,benefits and cost-effectiveness[J]?Br J Cancer,2013,108(1):9-13.